Conneqt Health Limited · ASX:CQT
Conneqt Health — Investor Presentation (December 2023)
46 slides from Conneqt Health's investor presentation, Dec 19, 2023
Slide 1: Biomarker technologies for cardiovascular health
1 Biomarker technologies for cardiovascular health December 2023
Slide 2: Important Notice and Disclaimer
2 IMPORTANT NOTICE AND DISCLAIMER The following notice and disclaimer applies to this presentation dated November 2023 (Presentation) and you should read this carefully before reading or making any other use of this Presentation or any information contained in this Presentation. By accepting, access
Slide 3: Financial data and rounding
3 Financial data and rounding: All dollar values are in Australian dollars (A$ or AUD) unless otherwise stated. The information contained in this Presentation may not necessarily be in statutory format. Amounts, totals and change percentages are calculated on whole numbers and not the rounded amount
Slide 4: Not an offer, advice or recommendation
4 Not an offer, advice or recommendation: This Presentation is for information purposes only and should not be read or understood as an offer, invitation, solicitation, inducement or recommendation to subscribe, buy or sell Shares, Options or any other financial products in any jurisdiction. This Pr
Slide 5: Corporate Overview
5 Corporate Overview • ASX listed MedTech (ASX:CDX). • US corporate based. • Developer of non-invasive vascular biomarker technologies for cardiovascular health • Q1 FY24 sales growth - 143% • Capital raise to launch multiple world-first technologies in new large scale health markets. • Largest shar
Slide 6: Investment Thesis
6 Investment Pioneering arterial health technology used by customers for over 20 years (AstraZeneca, Novartis, GSK, Bayer). Thesis New connected medical devices targeting a $293 billion market opportunity* with multiple new revenue streams. 5x FDA clearances to date. 4000+ installs. Unique reimburse
Slide 7: Targeting the Total Cost of Cardiovascular Disease Annually
7 Targeting the Total Cost of Cardiovascular Disease (CVD) Annually* World’s Largest Health $363B $1.1 Trillion Problems 2020 2035 #1 Cardiovascular (CV) disease is the 113M 19M Hypertensives in the USA Heart Disease Deaths Globally (50% of US Adults) (1 Every 36 Seconds in USA) Killer of humans glo
Slide 8: Significant Impact on Lifespan and Health Outcomes
8 Significant Impact on Lifespan and Health Outcomes EVA (Early Vascular Aging) 3x more likely to Normal Vascular Aging experience CV event (Arterial Stiffness + CV risk factors) “Central Hemodynamics Vascular Age Supernova measurement is essential because you (Supernormal Vascular Aging) don't die
Slide 9: A Complete Ecosystem of Vascular Biomarker Solutions
9 A Complete Ecosystem of Vascular Biomarker Solutions Current + Future (2024) Remote Patient Specialist Clinicians Monitoring XCEL & Oscar 2** Clinical Trials Pulse & Band*** Health Care Hospitals Providers & Pharma* Current Future Research Home Health *ATCOR provides on-site devices and data manag
Slide 10: Our Solution
10 Our Solution SphygmoCor Vascular Biomarker Technology ® Central Pulse XCEL* Pressure Subendocardial Not available Viability Ratio (SEVR) from traditional blood pressure monitors Central Blood Oscar 2* Pressure (ABPM) CONNEQT PULSE* SphygmoCor We non-invasively biomarkers represent capture arteria
Slide 11: Application Across Multiple Disease States
11 Application Across Multiple “Beyond Blood Pressure” “Beyond Hypertension” Disease States Our technology extracts data that impacts multiple disease states beyond hypertension. Brain & Preeclampsia Heart Disease Kidney/Renal Urology/Sexual Cognitive /Gestational Risk & Stroke Disease Health Health
Slide 12: Major Ongoing Trials and Studies
12 Major Ongoing 120+ Research Studies in Clinical Trials 46 Trials and Studies Process Using Our Technology To Date UK NHS Andwin Trial CARTESIAN Study Heart Failure Panacea Trial 2022 initiated trial between World's largest study on & Kidney Disease Assessment of vascular Andwin Scientific, Syneos
Slide 13: Our Current Customer Base
13 Our Current Customer Base Pharma/Biotech Clinical Research Organizations XCEL Oscar 2 (ABPM) Academic Researchers $ Specialist Healthcare Practices Sale | Lease | Data Services | Licensing 250+ research programs have used SphygmoCor biomarkers.* *Studies registered on the clinicaltrials.gov regis
Slide 14: Growth Fueled by New Products and Solutions
14 Growth Fueled by New Products and Solutions World-first Vascular Biometrics Monitor April/2023 World-first Dual-Sensor Arterial Health Wearable Anticipated FDA clearance Q3 CY24
Slide 15: For Professionals: Outcomes Monitoring
15 For Professionals: Outcomes Monitoring C A R D I E X D I G I T A L V A S C U L A R B I O M A R K E R S
Slide 16: For Individuals: Arterial Health Insights
16 For Individuals: Arterial Health Insights C A R D I E X D I G I T A L V A S C U L A R B I O M A R K E R S
Slide 17: World First Dual-Sensor Medical Grade Wearable
17 World First Dual-Sensor Medical Grade Wearable • Patent-pending side-sensor. • Dual health/fitness + vascular biometrics. • Medical grade (on anticipated FDA clearance). Anticipated FDA clearance Q3 CY24
Slide 18: 2023/24 New Product Launch Schedule
18 2023/24 New Product Launch Schedule 2023 2024 Product Solution H1 H2 H1 H2 Connected FDA Clearance Pre-Launch & GTM Planning Commercial Launch CONNEQT vascular PULSE biometric monitor. Gen. 1 CONNEQT Design & Development Commercial Launch CONNEQT app APP Remote patient CONNEQT Design & Developmen
Slide 19: Recognition & Traction
19 Recognition & Traction RADx ® Tech for Maternal Health se Finalist Challenge ha Fin a l P C A R D I E X D I G I T A L V A S C U L A R B I O M A R K E R S
Slide 20: Sector Growth Significantly Expanding Our Market Opportunity
20 Sector Growth Significantly Expanding Our Market Opportunity Remote Health Decentralized Patient Monitoring Wearables Clinical Trials $175B $104B $14B 2027 2027 2026 (Markets and Markets) (Grand View Research) (Medi-Tech Insights) https://www.marketsandmarkets.com/Market-Reports/remote- https://w
Slide 21: Our Growth Strategy
21 Our Growth Strategy 2025 From specialist clinician & research to cardiovascular healthcare at scale. Broad/Mass Market $$$ Medicare Advantage Managed Medicaid 2024 $$ Employees/Commercial Groups Managed Primary Care / HMOs / ACOs / IDNs Life Insurance Risk Management Licensing Concierge / Functio
Slide 22: GTM & Product Roadmap Aligned to Value-Based Care
22 GTM & Product Roadmap Aligned to Value-Based Care High VALUE Low C A R D I E X D I G I T A L V A S C U L A R B I O M A R K E R S RISK
Slide 23: Value-Based Care Strategy Supported by Three Market Trends
23 Value-Based Care Strategy Supported by Three Market Trends Phase in Pulse as we phase out XCEL over 36 months Clinic Patient Centered Centered One and Done 36 months Cloud-based Subscription Model Walled Garden Data Integration of Patient Data with EHRs
Slide 24: Value-Based Care Alignment Enables Sustainable 50% CAGRs
24 Value-Based Care Alignment Enables Sustainable 50% CAGRs To execute our GTM strategy, investment is required in People, Process, & Provisioning People Process/CRM Provisioning Demand Gen Team GTM Tracking & Reporting Customer Success Team Hired the first-ever demand gen Single source of truth for
Slide 25: Business Model
25 Business Model Monthly Subscription • Targeting providers and IDNs • $50 per device per month leased in packs of five • Decision-support, charting, and reporting • API-access for EHR integration C A R D I E X D I G I T A L V A S C U L A R B I O M A R K E R S
Slide 26: Our Competitive Moat
26 Our Robust sensor patent portfolio Competitive Moat World class engineering team Industry leading sector expertise Established presence, market validation, and Technology, process complexity category focus give us a & category focus competitive stronghold. 20+ years of research & development Only
Slide 27: Revenue Growth and New Product (Pre-Release) Launch
27 Revenue Growth and New Product (Pre-Release) Launch FY23 Financial Q1 FY24 FY24 Outlook Revenue $4.6m Revenue $1.3m Strong revenue growth Growth 13% Growth 143% Gross margin > 80% Gross margin > 80% Gross margin > 80% ATCOR + Product range Product range ATCOR Product range ATCOR CONNEQT CONNEQT P
Slide 28: Looking Ahead
28 Looking Ahead (6-12 months) • Multiple new product launch, partnership, and Solutions group. sales opportunities. • New clinical trial contracts and expansion of • Launch of brand, education, and demand existing trials. generation campaigns for CONNEQT. • Launch of multiple new studies for ongoin
Slide 29: Thank You
Thank You @ CARDIEX
Slide 30: Appendices
30 Appendices: - Sample Go-to-Market Highlights - Board & Senior Management - Key Risk Factors - Corporate Offices
Slide 31: Sample Go-to-Market Opportunity Highlights
31 Sample Go-to-Market Opportunity Highlights
Slide 32: Growth via Specific Condition Focus - Pregnancy
32 Growth via Specific Condition Focus - Pregnancy 1.6K Opportunity Highlight Maternal-Fetal Active Prospect: A Maternal-Fetal Medicine Clinic Medicine Number of Physicians: 3 Specialists Number of Deliveries: 3,000 per year $94M (1 per 14 OBGYN) Duration of Monitoring: 2nd - 4th trimester (10mo) Us
Slide 33: Growth via Concierge and Cash Pay Physicians
33 Growth via Concierge and Cash Pay Physicians Opportunity Highlight 43.5K Physicians use Active Prospect: A Concierge Network Number of Physicians: 50 Number of Patients: 7,000 concierge or direct- pay model # Device Sales: 48 per doc per year $59M Use Case: Hypertension and arterial health monito
Slide 34: Growth via Specific Condition Focus - Heart Failure
34 Growth via Specific Condition Focus - Heart Failure Opportunity Highlight $166M Active Prospect: A Specialist Cardiology Clinic Number of Physicians: 5 Number of Patients: 1,950 17K Duration of Monitoring: Ongoing Use Case: Monitoring and management of Cardiologists heart failure patients Annual
Slide 35: Growth via Specific Condition Focus - Alzheimer's
35 Growth via Specific Condition Focus - Alzheimer's $200M Opportunity Highlight Prospect: A Dementia Therapeutic Program 16K Number of Coaches 300 Patients per Coach: 5 Neurologists Annual Revenue $40M Potential $900K 0.02% 1% 5% 6.7 million patients % patients acquired Source:: Alzheimer's Disease
Slide 36: Board of Directors
36 Board of Directors Group CEO Executive Chairman Non-Executive Non-Executive Non-Executive CardieX/CONNEQT Health/ATC (Independent) Director (Independent) Director (Independent) Director OR Medical Craig Cooper Niall Cairns R. King Nelson Health/MedTech Medical Device Executive Marketing Executive
Slide 37: World Class Senior Management
37 World Class Senior Management Team with Health Tech Cuffless BP Growth Ninja Visionary Entrepreneur Track Record Craig R. Cooper Catherine Liao Josh Stevens CEO & Co-Founder Chief Strategy Officer President - CONNEQT Boost Mobile Blumio DayTwo of Success Saban Ventures Riverbed Crosslink Capital
Slide 38: Risk Factors
38 Risk Factors
Slide 39: Risk factors: risks specific to the Company
39 1. Risk factors Activities in the Company and its controlled entity, as in any business, are subject to risks, which may impact on the Company's future performance. The Company and its controlled entity have implemented appropriate strategies, actions, systems and safeguards for known risks, howe
Slide 40: Product Risks
40 (b) Product Risks The Company's success is closely tied to maintaining the value and reputation of its brands, which may not be as successful as anticipated. The Company's products and services may encounter design and manufacturing defects, whether real or perceived, which could have adverse eff
Slide 41: Cybersecurity risks
41 (e) Cybersecurity risks Expanding the Company’s solutions and capabilities that rely on network communications expose the Company to risks including cybersecurity threats, interruptions or delays in telecommunications systems, or data service losses, all of which could impair product and service
Slide 42: Industry risks
42 (h) Going concern The Company’s annual financial report for the year ended 30 June 2023 (Financial Report) includes a note in the independent auditor’s report on the financial condition of the Company and existence of a material uncertainty about the Company’s ability to continue as a going conce
Slide 43: Risks relevant to the Offers
43 (b) Competition The Company operates in a highly competitive market and may struggle to attract and retain users, hindering its business growth. As the health wearable market is relatively new, any failure of the general market or specific demand for the Company's products to meet expectations, o
Slide 44: General risks
44 1.4 General risks (a) Economic risks General economic conditions, introduction of tax reform, new legislation, movements in interest and inflation rates and currency exchange rates may have an adverse effect on the Company’s business activities and potential exploration and development programs,
Slide 45: Investment speculative
45 (e) Government and legal risk Changes in government, monetary policies, taxation and other laws can have a significant impact on the Company’s assets, operations and ultimately the financial performance of the Company and its Shares. Such changes are likely to be beyond the control of the Company
Slide 46: Global Presence
Global Presence SAN FRANCISCO/ SILICON VALLEY. Product Development CHICAGO Sales & Administration SHANGHAI Business Development and Operations IRVINE, CALIFORNIA Corporate & Executive SYDNEY APAC Corporate and Engineering
Conneqt Health — Investor Presentation (December 2023) on 6ix